Leuprorelin acetate depot vs danazol in the treatment of endometriosis: Results of an open multicentre trial

P. G. Crosignani, A. Gastaldi, P. L. Lombardi, U. Montemagno, M. Vignali, G. B. Serra, C. Stella

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

A national multicentre trial was organized in order to compare the efficacy and safety of leuprorelin acetate depot and danazol in the treatment of endometriosis. Sixty-seven patients with pelvic endometriosis of different severity at laparoscopy were included in the study and followed during the 24 weeks of treatment. Leuprorelin acetate depot 3.75 mg was injected every 24 days, while the daily dose of danazol was 600-800 mg. At the end of the study objective improvements induced by the two drugs were observed by a second laparoscopic examination. In addition, at regular intervals during the study semiquantitative evaluation of subjective symptoms were monitored. Scoring the final objective changes in the two patient groups revealed no significant difference, however the women treated with leuprorelin acetate depot registered significantly better control of pelvic pain. Due to its efficacy, tolerability and ease of use, leuprorelin acetate appears to be an excellent drug for the treatment of endometriosis.

Original languageEnglish
Pages (from-to)29-36
Number of pages8
JournalClinical Therapeutics
Volume14
Issue numberSUPPL. A
Publication statusPublished - 1992

Fingerprint

Leuprolide
Danazol
Endometriosis
Multicenter Studies
Acetates
Pelvic Pain
Symptom Assessment
Therapeutics
Pharmaceutical Preparations
Laparoscopy
Safety

ASJC Scopus subject areas

  • Pharmacology

Cite this

Crosignani, P. G., Gastaldi, A., Lombardi, P. L., Montemagno, U., Vignali, M., Serra, G. B., & Stella, C. (1992). Leuprorelin acetate depot vs danazol in the treatment of endometriosis: Results of an open multicentre trial. Clinical Therapeutics, 14(SUPPL. A), 29-36.

Leuprorelin acetate depot vs danazol in the treatment of endometriosis : Results of an open multicentre trial. / Crosignani, P. G.; Gastaldi, A.; Lombardi, P. L.; Montemagno, U.; Vignali, M.; Serra, G. B.; Stella, C.

In: Clinical Therapeutics, Vol. 14, No. SUPPL. A, 1992, p. 29-36.

Research output: Contribution to journalArticle

Crosignani, PG, Gastaldi, A, Lombardi, PL, Montemagno, U, Vignali, M, Serra, GB & Stella, C 1992, 'Leuprorelin acetate depot vs danazol in the treatment of endometriosis: Results of an open multicentre trial', Clinical Therapeutics, vol. 14, no. SUPPL. A, pp. 29-36.
Crosignani PG, Gastaldi A, Lombardi PL, Montemagno U, Vignali M, Serra GB et al. Leuprorelin acetate depot vs danazol in the treatment of endometriosis: Results of an open multicentre trial. Clinical Therapeutics. 1992;14(SUPPL. A):29-36.
Crosignani, P. G. ; Gastaldi, A. ; Lombardi, P. L. ; Montemagno, U. ; Vignali, M. ; Serra, G. B. ; Stella, C. / Leuprorelin acetate depot vs danazol in the treatment of endometriosis : Results of an open multicentre trial. In: Clinical Therapeutics. 1992 ; Vol. 14, No. SUPPL. A. pp. 29-36.
@article{f75a378774c740179c19ca0d03cf2e67,
title = "Leuprorelin acetate depot vs danazol in the treatment of endometriosis: Results of an open multicentre trial",
abstract = "A national multicentre trial was organized in order to compare the efficacy and safety of leuprorelin acetate depot and danazol in the treatment of endometriosis. Sixty-seven patients with pelvic endometriosis of different severity at laparoscopy were included in the study and followed during the 24 weeks of treatment. Leuprorelin acetate depot 3.75 mg was injected every 24 days, while the daily dose of danazol was 600-800 mg. At the end of the study objective improvements induced by the two drugs were observed by a second laparoscopic examination. In addition, at regular intervals during the study semiquantitative evaluation of subjective symptoms were monitored. Scoring the final objective changes in the two patient groups revealed no significant difference, however the women treated with leuprorelin acetate depot registered significantly better control of pelvic pain. Due to its efficacy, tolerability and ease of use, leuprorelin acetate appears to be an excellent drug for the treatment of endometriosis.",
author = "Crosignani, {P. G.} and A. Gastaldi and Lombardi, {P. L.} and U. Montemagno and M. Vignali and Serra, {G. B.} and C. Stella",
year = "1992",
language = "English",
volume = "14",
pages = "29--36",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica Inc.",
number = "SUPPL. A",

}

TY - JOUR

T1 - Leuprorelin acetate depot vs danazol in the treatment of endometriosis

T2 - Results of an open multicentre trial

AU - Crosignani, P. G.

AU - Gastaldi, A.

AU - Lombardi, P. L.

AU - Montemagno, U.

AU - Vignali, M.

AU - Serra, G. B.

AU - Stella, C.

PY - 1992

Y1 - 1992

N2 - A national multicentre trial was organized in order to compare the efficacy and safety of leuprorelin acetate depot and danazol in the treatment of endometriosis. Sixty-seven patients with pelvic endometriosis of different severity at laparoscopy were included in the study and followed during the 24 weeks of treatment. Leuprorelin acetate depot 3.75 mg was injected every 24 days, while the daily dose of danazol was 600-800 mg. At the end of the study objective improvements induced by the two drugs were observed by a second laparoscopic examination. In addition, at regular intervals during the study semiquantitative evaluation of subjective symptoms were monitored. Scoring the final objective changes in the two patient groups revealed no significant difference, however the women treated with leuprorelin acetate depot registered significantly better control of pelvic pain. Due to its efficacy, tolerability and ease of use, leuprorelin acetate appears to be an excellent drug for the treatment of endometriosis.

AB - A national multicentre trial was organized in order to compare the efficacy and safety of leuprorelin acetate depot and danazol in the treatment of endometriosis. Sixty-seven patients with pelvic endometriosis of different severity at laparoscopy were included in the study and followed during the 24 weeks of treatment. Leuprorelin acetate depot 3.75 mg was injected every 24 days, while the daily dose of danazol was 600-800 mg. At the end of the study objective improvements induced by the two drugs were observed by a second laparoscopic examination. In addition, at regular intervals during the study semiquantitative evaluation of subjective symptoms were monitored. Scoring the final objective changes in the two patient groups revealed no significant difference, however the women treated with leuprorelin acetate depot registered significantly better control of pelvic pain. Due to its efficacy, tolerability and ease of use, leuprorelin acetate appears to be an excellent drug for the treatment of endometriosis.

UR - http://www.scopus.com/inward/record.url?scp=0026718380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026718380&partnerID=8YFLogxK

M3 - Article

C2 - 1535020

AN - SCOPUS:0026718380

VL - 14

SP - 29

EP - 36

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - SUPPL. A

ER -